Conflict of interest
Novocure, cancer, MSK, Mesothelioma, Cancer
VIRUS, CANCER, MALIGNANT PLEURAL EFFUSION, MESOTHELIOMA, CANCER
In the last 3 years, MZ has received consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, and Novocure and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by MZ. MZ serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated. PA declares research funding from ATARA Biotherapeutics; Scientific Advisory Board Member and Consultant for Abound Bio, ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnson&Johnson, Orion Pharma, Outpace Bio, Pleuri-tech, Putnam associates; Patents, royalties and intellectual property on mesothelin-targeted CAR and other T-cell therapies licensed to ATARA Biotherapeutics, issued patent method for detection of cancer cells using virus, and pending patent applications on PD-1 dominant negative receptor, wireless pulse-oximetry device, and on an ex vivo malignant pleural effusion culture system. Memorial Sloan Kettering Cancer Center MSK has licensed intellectual property related to mesothelin-targeted CARs and T-cell therapies to ATARA Biotherapeutics, and has associated financial interests.The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.